Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05551104 · ClinicalTrials.gov registry record · Phase 3

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

A Phase 3 study of High Blood Pressure and Postpartum Complication, sponsored by Loma Linda University.

Recruiting
Registry status
Phase 3
Development phase
500
Enrollment target
1
Study location

NCT05551104 is a Phase 3 study of High Blood Pressure and Postpartum Complication that is actively recruiting participants, run by Loma Linda University. The registered enrollment target is 500 participants, roughly in line with the 483-participant average among 23 other High Blood Pressure trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05551104, a Phase 3 study of High Blood Pressure and Postpartum Complication, is actively recruiting participants, sponsored by Loma Linda University.

RECRUITING
Registry status
Phase 3
Development phase
500 participants
Enrollment target
1
Study location

Study Summary

The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.

Interventions

  • DRUG Oral Nifedipine
  • DRUG Oral Labetalol

Study Locations (1)

California

  • Loma Linda University Health - Loma Linda

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2023-05-08
Est. Completion 2027-12
Phase Phase 3

Sponsor

Loma Linda University

237 total trials

What the Registry Record Tells You About NCT05551104

The ClinicalTrials.gov registry entry for NCT05551104 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 483-participant average among 23 other High Blood Pressure trials with a reported enrollment target. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with High Blood Pressure appearing as the primary indexed condition, and to 2 interventions - of which Oral Nifedipine is the first listed.

NCT05551104 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05551104 about?

NCT05551104 is a clinical study titled "Safest Choice of Antihypertensive Regimen for Postpartum Hypertension". The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.

What is the current status of trial NCT05551104?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-05-08. Estimated completion is 2027-12.

What conditions does trial NCT05551104 study?

This clinical trial studies the following conditions: High Blood Pressure, Postpartum Complication, Maternal Hypertension.

What interventions are being tested in trial NCT05551104?

The interventions under investigation include: Oral Nifedipine (DRUG), Oral Labetalol (DRUG).

Who is sponsoring clinical trial NCT05551104?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05551104 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for High Blood Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.